45 results about "Peripheral blood cell" patented technology

The invention discloses an application of CD4 + CD8 + double-positive T cells in improvement of poor immune reconstitution of HIV (human immunodeficiency virus) infected patients, and relates to the technical field of biological pharmacy, in particular to the application of preparation of the CD4 + CD8 + double-positive T cells in the poor immune reconstitution of the HIV infected patients. The number of peripheral blood CD4 + T cells of HIV infected patients is increased, the immune system of the patients is improved, and the probability of possible opportunity infection and other related diseases of the patients is reduced, so that the morbidity and mortality of the patients are reduced.

The invention discloses a Wright staining peripheral blood cell accurate identification system and method based on intelligent microscopic imaging and multi-modal fusion deep learning, belongs to the crossing field of medical examination and artificial intelligence, and is suitable for cell morphology analysis under a 10 * 40-time microscope. The core scheme comprises the following steps: standardized slide preparation and dyeing (the slide pushing angle is 25 + / -2 degrees, the pH is 6.8 + / -0.2, and color sensing dynamic regulation is performed); intelligent imaging (focusing formula and color normalization; the method comprises the following steps of (1) data processing, (2) data processing, (3) data processing, (4) data processing, (5) data processing, (6) data processing, (7) data processing, (8) data processing, (7) data processing, (8) data processing, (8) data processing, (8) data processing, (8) data processing, (8) data processing and (8) data processing.

The invention provides an ischemic stroke auxiliary diagnosis system based on a peripheral blood T cell single cell transcriptome and application thereof, and the auxiliary diagnosis system comprises a peripheral blood mononuclear cell acquisition module, a single cell RNA sequencing module, a data processing module, a data analysis module and a result discrimination module. With a coding gene of a protein molecule significantly related to the occurrence of ischemic stroke as a target gene, a data processing module obtains the expression level of the target gene in each T cell; the data analysis module obtains a risk score of each T cell of the subject by using a built-in single cell risk scoring model, and weights the risk scores of all the T cells through distributed perception identification to obtain an individual risk score of the subject; and the result judgment module is used for classifying the subjects into ischemic stroke negative and ischemic stroke positive according to the individualized risk scores of the subjects. The auxiliary diagnosis system disclosed by the invention is high in ischemic stroke discrimination capability, and high in sensitivity and specificity.

The present application relates to the application of Bifidobacterium longum subsp.longum BL21 in the preparation of a preparation for improving hematopoietic dysfunction, wherein the Bifidobacterium longum subsp.longum BL21 is a Bifidobacterium longum subsp.longum BL21 strain with a preservation number of CGMCC No.10452.The present application develops a new microbial strategy for improving hematopoietic dysfunction, and uses the Bifidobacterium longum subsp.longum BL21 in the preparation of a preparation for improving hematopoietic dysfunction.It is found that the Bifidobacterium longum subsp.longum BL21 can increase the number of peripheral blood cells (red blood cells and white blood cells), the content of platelets or the content of hemoglobin, reverse the weight loss caused by hematopoietic dysfunction, and improve the serum inflammatory response and the spleen inflammatory response caused by hematopoietic dysfunction.The present application also provides a new idea for the wide application of the Bifidobacterium longum subsp.longum BL21.

The invention belongs to the technical field of tumor immunotherapy, and relates to an anti-Claudin18.2 single-domain antibody, a multifunctional fusion protein, a recombinant natural killer cell (CT-CAR-NK), and preparation and application thereof. Through alpaca immunization and phage display library construction and panning, the single-domain antibody VHH-C18.2-1 specifically combined with Claudin18.2 is obtained, and the amino acid sequence of the single-domain antibody VHH-C18.2-1 is SEQ ID NO: 1. The amino acid sequence of the designed fusion protein is SEQ ID NO: 3, the fusion protein sequentially comprises a VHH-C18.2-1, a flexible Linker, a TGF-beta RII extracellular domain, a CD8alpha hinge region, a CD8alpha transmembrane region, a 4-1BB intracellular domain and a CD3zeta intracellular domain from the N end to the C end, and the fusion protein has the functions of targeting, resisting TGF-beta inhibition and activating signals. The fusion protein gene transfects human peripheral blood CD56 + CD3-NK cells through lentivirus to obtain CT-CAR-NK, in-vitro verification shows that the CT-CAR-NK still keeps efficient killing in an immunosuppression environment, tumor growth can be remarkably inhibited in vivo, the lifetime can be prolonged, and a safe and efficient scheme is provided for Claudin18.2 positive solid tumor treatment.

The invention relates to a quality control substance for flow cytometry HLA-B27 analysis as well as a preparation method and application of the quality control substance. The quality control substance comprises a negative quality control substance and a positive quality control substance; the negative quality control substance comprises human lymphocyte negative quality control substance simulation particles and human peripheral blood cells or simulation particles; an HLA-B27 antigen is not expressed on the surface of the human lymphocyte negative quality control substance mimic particle; the positive quality control substance comprises human lymphocyte positive quality control substance simulation particles and human peripheral blood cells or simulation particles; an HLA-B27 antigen is expressed on the surface of the human lymphocyte positive quality control substance simulation particle; cD3 antigens and CD45 antigens are expressed on the surfaces of the human lymphocyte positive quality control substance simulation particles and the human lymphocyte negative quality control substance simulation particles. The technical problem to be solved is how to provide a quality control substance which is good in stability and can be applied to flow cytometry HLA-B27 analysis.

Provided in the present invention is a grading method for evaluating the severity of the clinical symptoms of hypersplenism. In the present invention, a model for evaluating the severity of the clinical symptoms of hypersplenism is constructed by means of performing logistic regression analysis on PLT, WBC and RBC to establish a nomogram, converting regression coefficients into a visual scoring system, separately performing score assignment on the basis of primary and secondary factors, and finally constructing a total-score-based hypersplenism grading prediction model. The model in the present invention is used to evaluate the severity of the clinical symptoms of hypersplenism in patients. By means of correlation analysis of peripheral blood cell testing results of patients with hypersplenism, hypersplenism grades of the patients are evaluated, such that personalized treatment plans can be provided to the patients in a timely manner, thereby avoiding delays in treatment.

This useful solution, in the field of biotechnology and regenerative medicine, relates to a process for enhancing the efficiency of induced pluripotent stem cell (iPSC) colony formation from human peripheral blood mononuclear cells (PBMCs). The solution aims to overcome the low reprogramming efficiency, unstable colony formation, and limited iPSC cloning rates commonly encountered in PBMC iPSC generation processes. The technical essence of the solution lies in the synchronized optimization of the reprogramming process, including pre-activating PBMCs with an appropriate cytokine combination at predetermined times before reprogramming, using a non-integrated Sendai virus system under optimized transformation conditions, switching culture media at defined intervals to promote cell state transitions, and applying a selection, enrichment, and stabilization process for iPSC cloning in the initial passages after colony formation.The process also incorporates cell line quality control steps through assessment of residual Sendai virus RNA removal and mycoplasma contamination testing during line maintenance. Experimental results show that the proposed process increases the number of iPSC colonies formed, improves the rate of establishing stable iPSC lines, and enhances cell homogeneity and pluripotency maintenance. The solution can be applied in basic research, pathogenesis modeling, drug screening, regenerative medicine, and studies using induced pluripotent stem cells derived from human peripheral blood cells.

The invention relates to application of a traditional Chinese medicine composition in preparation of a medicine for preventing or treating myelodysplastic syndrome and related complications thereof. The traditional Chinese medicine composition comprises sculellaria barbata, astragalus membranaceus, angelica sinensis, nightshade, radix curcumae, red ginseng, duchesnea indica, saussurea involucrata, cyclea verticillata and salvia miltiorrhiza. The traditional Chinese medicine composition has a good prevention and treatment effect on myelodysplastic syndrome and related complications thereof, can effectively inhibit proliferation of hematological tumor cells, and also can inhibit proliferation of the myelodysplastic syndrome by increasing the hemoglobin level, reducing the inflammatory cytokine level and reducing the proportion of peripheral blood T cells. Anemia, inflammation and low immune function caused by the myelodysplastic syndrome can be treated. The invention provides an effective strategy for prevention or treatment of myelodysplastic syndrome and related complications thereof, and provides a new direction for application of the traditional Chinese medicine composition.

The application belongs to the technical field of biological medicine, and particularly relates to a TCR sequence targeting KRAS G12D antigen and application thereof. The CDR3 region of a wild type TCR is rationally designed and optimized through a simulation docking technology, and an optimized TCR with significantly improved affinity is obtained. Experimental results show that the TCR-T cell (human peripheral blood T cell TCR Homo sapiens) can effectively kill solid tumor cells, inhibit tumor growth in vivo and in vitro, improve the T cell immunotherapy effect, and can be used for preparing a cell drug for solid tumors, and has the advantages of high safety, strong targeting, significant effect and the like. The application provides a new drug selection and treatment scheme for the treatment of solid tumors.

The invention discloses a wolfberry-astragalus compound polysaccharide with an anti-myelosuppression effect as well as a preparation method and application of the wolfberry-astragalus compound polysaccharide. The wolfberry-astragalus compound polysaccharide is prepared by adopting a process of separately extracting wolfberry polysaccharide and astragalus polysaccharide and then mixing, the total sugar content is 70-80%, the uronic acid content is 10-14%, and the wolfberry-astragalus compound polysaccharide has specific molecular weight distribution and monosaccharide composition characteristics. Animal experiment results show that the wolfberry and astragalus compound polysaccharide can significantly improve peripheral hemopenia of myelosuppression mice induced by cyclophosphamide, promote recovery of the number of leukocytes, lymphocytes, monocytes and neutrophils, and effectively reverse weight loss caused by chemotherapeutic drugs. The wolfberry-astragalus compound polysaccharide provided by the invention is high in safety and remarkable in anti-myelosuppression effect, and can be used for preparing medicines or functional preparations for improving myelosuppression related diseases.

The invention belongs to the technical field of biological medicine, and discloses application of JAM3 protein in preparation of a medicine for inhibiting formation of a neutrophil extracellular trapping net. JAM3 is an I-type single transmembrane protein containing 310 amino acids, and belongs to an immunoglobulin superfamily. Researches show that the JAM3 protein remarkably inhibits excessive formation of a sepsis neutrophile granulocyte extracellular trapping net by regulating and controlling an activation path of neutrophile granulocytes, and meanwhile prevents blood platelets from being excessively captured, so that formation of microthrombus in the liver and damage to organs are avoided, disease progression is effectively controlled, and recovery of peripheral blood cells and organisms is promoted.

The invention discloses an in-vitro amplification method for improving the purity of natural killer cells. The use combination of the cell factors is IL-2, IL-15, IL-18 and IL-21, the culture of the umbilical cord blood NK cells is optimized mainly from the aspects of the factor combination used for culturing the NK cells, the use concentration and the like, CD3-CD56 + positive indexes all reach 80% or above, and the amplification rate reaches 100 times or above. The method is also suitable for large-scale culture of peripheral blood NK cells, the CD3-CD56 < + > positive rate reaches 99.0% or above, the amplification rate reaches 1000 times or above, and the killing rate of K562 cells is 30% or above when the effect-target ratio is 1: 1.

The invention provides a method for in-vitro amplification and induced activation of iNKT cells, and belongs to the technical field of immune cell preparations. The in-vitro amplification method comprises the following steps: S1, separating peripheral blood PBMCs cells; s2, adding a part of PBMCs into a culture medium I for stimulation culture and irradiation, and separating to obtain irradiated PBMCs; s3, re-suspending the other part of PBMCs cells in a culture medium II, adding alpha-GalCer and IL-2 to stimulate culture, then adding the irradiated PBMCs cells, and amplifying iNKT cells; the induction and activation method comprises the following steps: amplifying the iNKT cells, adding a culture medium III, adding a dasatinib derivative, and inducing the iNKT cells to be mature. According to the method, amplification and induced activation of the iNKT cells can be rapidly promoted, the amplification efficiency is high, the obtained iNKT cells are high in cytotoxicity, the method is safe, and graft versus host reaction is not caused.

The application belongs to the technical field of biological medicine, and particularly relates to application of TREM-2 in preparation of a therapeutic drug and / or a diagnostic reagent for multiple sclerosis. The application research finds that TREM-2 is highly expressed in peripheral blood CD4+ T cells of multiple sclerosis patients, and positively correlated with the severity of the disease, indicating that TREM-2 can be used as a diagnostic marker for multiple sclerosis. The marker can be taken from peripheral blood, and has the characteristics of small trauma, low cost, rapidness and high sensitivity compared with other examinations such as cerebrospinal fluid examination, evoked potential and head CT, magnetic resonance imaging and the like. The application also finds that TREM-2 is involved in the transformation of pathogenic Th17 cells and the secretion of IL-6 and IL-17, indicating that intervention of the expression of TREM-2 can relieve and even hopefully treat multiple sclerosis.

Methods, devices, and systems for managing peripheral blood cells are provided. In one aspect, a fully automatic peripheral blood separation method includes: adding a peripheral blood sample liquid in a sample bag and a gradient liquid into a centrifuge cup, collecting a target cell liquid into an intermediate bag after centrifugation of the peripheral blood sample liquid and the gradient liquid in the centrifuge cup, adding the target cell liquid in the intermediate bag and a washing liquid to the centrifuge cup for washing and replacement to obtain a pre-product, and mixing the pre-product and a cell dilution liquid to obtain a final product.

The invention provides a biomarker screening method and system for radiotherapy-immunity pneumonia prediction, and relates to the technical field of biomedicine. Aiming at the problem that the timeliness and the specificity of the existing radiotherapy-immunity pneumonia diagnosis cannot be considered at the same time, the method comprises the following steps: separating peripheral blood T cells of a radiotherapy-immunity pneumonia group and a control group, carrying out T cell clustering annotation in combination with single-cell secretory proteomics, an R language and an ImMen database, and screening a key T cell subset Tc17 by utilizing an Augur algorithm; the method comprises the following steps: determining pericytes as key interaction cells of Tc17 through cell interaction analysis, and screening a radiotherapy specific up-regulation gene MFAP4; and carrying out difference analysis on the Mfap4hi week cell subpopulation, and screening out a biomarker gene set containing 18 genes on the basis of an elastic network algorithm in combination with 3-fold nested cross validation. The invention provides a key basis for early prediction and accurate intervention of radiotherapy-immunity pneumonia, and has the advantages of high specificity and strong repeatability.

The application relates to the field of biological medicine, and particularly discloses a monoclonal antibody combined with human CD8 and a preparation method and application thereof. The antibody is obtained by combining single B cell sorting, gene cloning and mammalian cell expression technology after rabbit immunization of a CD8 polypeptide antigen, a New Zealand white rabbit is immunized by adopting a KLH coupled CD8 antigen polypeptide combined with a rapid immunoadjuvant, high-affinity antibody clones are obtained by single B cell sorting technology, and the antibody is prepared by recombination expression. The antibody is verified by ELISA and flow cytometry, has high titer and strong specificity, can effectively recognize human peripheral blood CD8+ T cells, and has a signal strength and a background signal-to-noise ratio which are significantly better than those of a traditional mouse-derived antibody. The application provides light and heavy chain variable region amino acid sequences of the antibody, realizes controllable preparation of the antibody and protection of intellectual property rights. The antibody can be widely applied to the fields of flow cytometry detection, immunohistochemistry, tumor immunotherapy monitoring and T cell function research, and has important scientific research and clinical application values.

The invention relates to a method for in vitro transformation of hematopoietic stem / progenitor cells (HS / PCs) and blood cells from adipose-derived mesenchymal stem cells (Ad MSCs). The method comprises the following steps: acquiring biological cells of an individual; purifying and amplifying the biological cells; a purified (single) Ad MSCs cell line is obtained from the amplified biological cells; the purified (single) Ad MSCs cell line is converted into HS / PCs in vitro; exogenous genes are not introduced in the in-vitro transformation process; continuously amplifying the transformed HS / PCs in vitro; and finally, the amplified HS / PCs and peripheral blood cells are obtained.

The application discloses peripheral blood CD8 + The application discloses an application of T cell absolute count as a biomarker in prevention or evaluation of pulmonary lymphangioleiomyomatosis. The application breaks the limitation of traditional methods mainly depending on imaging or single serological index, provides a novel diagnosis strategy based on peripheral blood immune cell absolute count, is convenient for sampling (venous blood can be drawn), has low detection cost, can be used for dynamic monitoring of patient's disease severity and prognosis stratification, and lays a solid foundation for subsequent development of immune regulation target drugs for S-LAM.

This invention belongs to the field of biomedical technology and discloses the application of CCR2 inhibitors in the preparation of drugs for treating hemophagocytic lymphohistiocytosis (HLH). By establishing a mouse model of HLH, this invention reveals for the first time that CCR2 can serve as an effective drug target for treating HLH. Experiments showed that treatment with the CCR2-specific antagonist RS102895 significantly reduced splenomegaly, improved peripheral blood cell reduction, alleviated liver damage, corrected metabolic disorders in model mice, and effectively inhibited serum cytokine storm and abnormal activation of splenic macrophages. Based on these findings, CCR2 can serve as a novel target for HLH treatment, and its inhibitors can be used to prepare highly effective and low-toxicity drugs for treating HLH.

To provide anti- CD19 antibodies for use in treating patients with hematological cancers, and to provide methods for selecting patients with hematological cancers who are predicted to benefit from therapeutically administering anti- CD19 antibodies.SOLUTION: The present invention provides features and biomarkers in patients who benefit from treatment with anti- CD19 antibodies (MOR00208, XmAb5574). In addition, the application provides anti- 100NK antibodies for the treatment of leukemias or lymphomas in patients with peripheral NK cell counts equal to or less than CD19 cells / μ l at baseline.SELECTED DRAWING: Figure 1

This invention describes new methods for the mobilization of human cells such as hematopoietic stem cells in bone marrow, and the subsequent collection of such cells from the peripheral blood of deceased donors. These methods produce quantities of hematopoietic stem cells that can be used in a multitude of possible applications without harming the deceased donor or the recovery of the deceased donor's organs for solid organ transplantation. The methods involve the administration of one or more mobilizing agents to mobilize bone marrow cells into the peripheral blood cells followed by the collection of cells via apheresis.

The invention relates to the technical field of biological medicines, and particularly discloses a monoclonal antibody combined with human CD8 as well as a preparation method and application of the monoclonal antibody. The antibody is obtained by immunizing a rabbit with a CD8 polypeptide antigen and combining single B cell sorting, gene cloning and mammalian cell expression technologies, a New Zealand white rabbit is immunized by adopting KLH coupled CD8 antigen polypeptide and combining a rapid immunologic adjuvant, high-affinity antibody clone is obtained through the single B cell sorting technology, and the antibody is prepared through recombinant expression. Through ELISA and flow cytometry verification, the antibody is high in titer and strong in specificity, can effectively recognize human peripheral blood CD8 + T cells, and is remarkably superior to a traditional mouse antibody in signal strength and background signal-to-noise ratio. The invention provides an amino acid sequence of a light and heavy chain variable region of the antibody, and controllable preparation and intellectual property protection of the antibody are realized. The antibody can be widely applied to the fields of flow cytometry detection, immunohistochemistry, tumor immunotherapy monitoring, T cell function research and the like, and has important scientific research and clinical application values.

Schizophrenia (SCZ) is the most debilitating of the Serious Mental Illnesses, a group of disorders affecting 4.8% of Arizona adults. The lack of a biologically based test makes diagnosing SCZ difficult, particularly for the 40% of Arizonans in areas with inadequate mental health care. Even under ideal circumstances, it can take months to years to accurately diagnose SCZ and identify an effective medication regimen. There is a critical need to identify biological markers to rapidly diagnose SCZ, which will lead to faster symptom resolution and improved patient outcomes. Methods described herein capitalize on the long-recognized association between SCZ risk and immune system dysfunction by stimulating peripheral blood immune cells with immunogenic agents to gain insight into disrupted pathways of gene expression in the brain. The immune stimulation of peripheral blood cells produces a unique pattern of gene expression, which will differ between SCZ and healthy control subjects.

Systems and methods for mitigating prostate cancer development are provided. Peripheral blood cells may be evaluated for the presence or quantity of gamma-H2AX foci, and / or for gene alterations encoding a protein with impaired or lack of function, for example, because the encoded protein is truncated, and correlating with prostate cancer development. Such nucleic acids may encode proteins from or peripheral to the DNA damage repair pathway and / or androgen receptor signaling pathway, or that are otherwise correlated with prostate cancer development. Such genes include one or more of AKR1C1, PALB2, APTX, BLM, BRCA1, CTBP1, DDB2, FANCA, FANCL, MBD5, MSH3, NEIL3, RAD51D, RAD54L2, SP1, TP53BP1, UBE2D3, UBE2V2, NRIP1, EFCAB6, CRISP3, PAPSS2, ATP6V0A2, ALG13, MGAT2, B3GAT3, DOLK, FLT3, ASXL1, KDR, or NOTCH2.

This invention discloses a probe for detecting Ox-LDL and its applications, belonging to the field of Ox-LDL detection technology. This invention provides a variety of probe molecules that can specifically and sensitively recognize Ox-LDL and effectively distinguish between high-density lipoprotein (HDL), low-density lipoprotein (LDL), and Ox-LDL. The probe exhibits significantly enhanced fluorescence in the presence of Ox-LDL, while showing almost no fluorescence in pure PBS solution, with low background noise. The probe of this invention is a molecular probe, simple to prepare, stable, easy to store and detect, and can be used as a reagent for detecting Ox-LDL in peripheral blood, cells, and tissues, a lipoprotein identification reagent, an early diagnostic reagent for atherosclerosis, and an early diagnostic reagent for fatty liver.